EMA Looks At Avastin, As Novartis/Roche Appeal Italian Competition Fines
This article was originally published in The Pink Sheet Daily
With EMA deliberating about Avastin, Novartis and Roche have confirmed that they will appeal the €180.5 million fine imposed on them by Italy’s competition authority for anti-competitive behavior.
You may also be interested in...
EFPIA, Novartis and Roche believe that a decision by the Italian regulatory authority, AIFA to allow reimbursement for the off-label use of Avastin in place of Lucentis may be against EU law.
The Italian government has said it will pursue Roche and Novartis for €1.2 billion it says the Swiss companies owe to its health service for anticompetitive activities involving Avastin and Lucentis.
Pharmaceutical and biotech companies in Europe take heart from IPOs and new governmental schemes to improve patients’ early access to innovative medicines, while fresh calls are made for an integrated, over-arching European industrial strategy for the life sciences sector.